Jessica Merrill

Jessica Merrill

Senior Editor

Brooklyn, NY

Jessica is a senior editor, contributing most frequently to daily pharmaceutical coverage in Scrip and Pink Sheet. With a lengthy career covering the pharmaceutical sector, she specializes primarily in business and commercial news, launch strategy, M&A and market access issues.

Latest from Jessica Merrill

Lilly’s Head-To-Head Trial Reaffirms Zepbound Efficacy Versus Wegovy

Zepbound led to greater weight loss versus Wegovy in a Phase III trial, bolstering its position as the superior product in the fast-growing obesity space.

Keros Monetizes Hematology Asset In Deal With Takeda

Takeda will pay $200m up front for rights to Phase II elritercept for anemia in patients with MDS and myelofibrosis, allowing Keros to extend its cash runway to 2028.

Leo Pharma Picks Up Momentum As Growth Plan Progresses

CEO Christophe Bourdon talked to Scrip about the company’s revitalization as revenue grew 10% in the third quarter.

The Scrip 100: Changes At The Top Of The Leaderboard

Pfizer continued its reign as the Scrip 100 leader for a third year, while Lilly and Novo climbed higher.

Novartis Gains Next-Generation Gene Therapy Tech With Kate Acquisition

The Swiss pharma acquired Kate Therapeutics for up to $1.1bn, gaining preclinical gene therapies for neuromuscular conditions and novel platform technology.

Pfizer Picks Boshoff To Head R&D, A Smooth Transition In An Uncertain Time

Chris Boshoff has been with Pfizer more than 10 years and has led oncology R&D and the integration of Seagen. He will succeed Mikael Dolsten, who will depart after leading R&D for nearly 15 years.